Nexeon MedSystems Belgium is developing an innovative and non-invasive neurostimulation product for the treatment management of patients suffering from atrial fibrillation (AF). AF is the most common arrhythmia diagnosed in clinical practice and is predicted to affect 17.9 million people in Europe by 2060 and 6–12 million people in the USA by 2050. ...
Read More
Development of a neuronal technology to detect and treat attention deficit hyperactivity disorder (ADHD) NeuroAtt aims to design novel electrophysiological diagnostic tools (EDT) and brain wave trainers (BWT) in attention deficit hyperactivity disorder (ADHD). It includes the development of methods to analyse multi-channel EEG recordings during sensorimotor and cognitive tasks...
Read More
For the past ten years, researchers and doctors have considered sleep as a major public health issue. In particular, sleep apnea syndrome is frequently cited. At each interruption of breathing, your heart and your brain are under stress. Night after night your sleep is disturbed, your quality of life is...
Read More
10 million people worldwide are suffering from Parkinson's disease and this number is likely to double over the next 10 to 15 years. There is no cure yet. Parkinson's disease is the fastest growing neurodegenerative disease. The disease is complex, as over 60 symptoms can appear. A personalised care path is therefore critical for...
Read More